Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer

Journal of Clinical Gastroenterology

Volumn 48, Issue 5, 2014, Pages 430-434

  Khoja, Leila ^a   Kumaran, Gireesh ^a   Zee, Ying Kiat ^a   Murukesh, Nishanth ^a   Swindell, Ric ^a   Saunders, Mark P ^a   Clamp, Andrew R ^a   Valle, Juan W ^a   Wilson, Greg ^a   Jayson, Gordon C ^a   Hasan, Jurjees ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

biomarker; colorectal cancer; hypertension; proteinuria; response

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; VASCULOTROPIN A;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; EVALUATION STUDY; FEMALE; HUMAN; HYPERTENSION; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PROTEINURIA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898600792     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182a8804c     Document Type: Article

References (23)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
3. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86: 353-364.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
5. Shaked Y, Bocci G, Munoz R, et al. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets. 2005;5:551-559.
6. Hurwitz H. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer. 2004;4(suppl 2):S62-S68.
7. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
9. Van Cutsem E, Sobrero AF, Siena S, et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts. 2012;30:3502.
10. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem. 1999;274:33057-33063.
11. Granger JP, Alexander BT. Abnormal pressure-natriuresis in hypertension: role of nitric oxide. Acta Physiol Scand. 2000; 168:161-168.
12. Robinson ES, Khankin EV, Choueiri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension. 2010;56:1131-1136.
13. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50:203-218.
14. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010;46:439-448.
15. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
16. Horsley L, Marti K, Jayson GC. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol. 2012;8:283-293.
17. Osterlund P, Soveri LM, Isoniemi H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer. 2011;104:599-604.
18. De Stefano A, Carlomagno C, Pepe S, et al. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol. 2011;68:1207-1213.
19. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20: 227-230.
20. Dewdney A, Cunningham D, Barbachano Y, et al. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer. 2012;106: 1718-1721.
21. Burnette BL, Grothey A. Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX. ASCO Meeting Abstracts. 2010;28:e14066.
22. Mourad JJ, des Guetz G, Debbabi H, et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927-934.
23. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305:487-494.